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Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has shown a 
remarkable reduction in cardiovascular and all-cause mortality in patients with type 2 diabetes 
(T2D) and antecedents of cardiovascular disease in the EMPA-REG OUTCOME trial. This 
effect has been attributed to a hemodynamic rather than a metabolic effect, partly due to the 
osmotic/diuretic effect of empagliflozin and to the reduction in arterial blood pressure. The 
present review will : 1) summarize the results of specific studies having tested the blood 
pressure lowering effects of SGLT2 inhibitors;  2)  describe the results of meta-analyses of 
trials having evaluated the effects on mortality and cardiovascular outcomes of lowering 
blood pressure in patients with T2D, with a special focus on baseline and target blood 
pressures; 3) compare the cardiovascular outcome results in EMPA-REG OUTCOME versus 
other major trials with antihypertensive agents in patients with T2D; and 4) evaluate post-hoc 
analyses from EMPA-REG OUTCOME, especially subgroups of patients of special interest 
regarding the blood pressure lowering hypothesis. Although BP reduction associated to 
empagliflozin therapy may partly contribute to the benefits reported in EMPA-REG 
OUTCOME, other mechanisms most probably play a greater role in the overall CV protection 
and reduction in mortality observed in this trial.  
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Arterial hypertension is frequently associated with type 2 diabetes (T2D). These two 
bad companions markedly increase the risk of cardiovascular (CV) disease and premature 
death [1], and each of them, T2D [2] and hypertension [3], are well known independent CV 
risk factors. In the landmark United Kingdom Prospective Diabetes Study (UKPDS), reducing 
blood pressure (BP) in patients with newly diagnosed T2D and rather high BP resulted in a 
remarkable diminution in the incidence of diabetes-related complications, among which CV 
events and CV mortality [4]. These favourable results, in fact better than those obtained with 
intensive glucose lowering strategy [5], were confirmed in further studies  having recruited 
patients with more advanced T2D and higher CV risk but better controlled BP such as 
MICRO-HOPE [6] and ADVANCE-BP [7]. A recent meta-analysis by the “Blood Pressure 
Lowering Treatment Trialists, Collaboration” showed that lowering BP provides similar 
relative protection at all levels of baseline CV risk, but progressively greater absolute risk 
reductions as baseline risk increases [2], and it is well known that T2D markedly increases the 
risk of CV disease [8]. Nevertheless, even if lowering BP in patients with arterial 
hypertension showed a remarkable reduction in CV complications, including myocardial 
infarction, stroke, congestive heart failure, CV mortality and all-cause mortality, a significant 
interaction was detected for major CV events when trials were stratified by baseline diabetes 
(yes or no), with significantly larger risk reductions for populations without diabetes than in 
populations with diabetes [9]. It is noteworthy, however, that this interaction was not found in 
another meta-analysis focusing on patients at high CV risk, which rather showed a trend for 
slightly greater reduction in major cardiovascular events (MACEs) among patients with T2D 
versus patients without diabetes [10]. Finally, despite the well demonstrated benefit of 
lowering BP in diabetes [11], BP targets in patients with T2D [12] as well in patients with 





After the UKPDS [5], most CV outcome trials with glucose-lowering agents gave 
rather disappointing results [15-18]. Dipeptidyl peptidase-4 inhibitors (gliptins), which exert 
almost a neutral effect on BP [19], proved non-inferiority but no superiority versus placebo, 
demonstrating the CV safety of this pharmacological class but not its efficacy in preventing 
CV events [20]. Of major interest, superiority versus placebo was recently reported in EMPA-
REG OUTCOME with empagliflozin [21], a sodium-glucose cotransporter type 2 (SGLT2) 
inhibitor that reduces arterial BP, and, to a less extent, in LEADER with liraglutide [22], a 
glucagon-like receptor agonist that was also associated with a modest, but significant, BP 
reduction.  
SGLT2 inhibitors are novel glucose-lowering agents indicated for the treatment of 
patients with T2D [23]. These compounds have a distinct mechanism of action in the renal 
proximal tubule, by blocking the reabsorption of glucose. Besides promoting glucosuria, they 
can exert pleiotropic effects, which could reduce several CV risk factors and potentially CV 
complications [24, 25]. Among these pleiotropic effects, a reduction in arterial BP has been 
consistently reported with all SGLT2 inhibitors [26-29]. In patients with T2D and CV 
antecedents enrolled in the placebo-controlled EMPA-REG OUTCOME landmark trial, the 
addition of empagliflozin to standard care was associated with a significant reduction in the 
primary endpoint, a composite of CV mortality, non-fatal myocardial infarction and non-fatal 
stroke (so-called triple MACE) [21]. The reduction in CV mortality, which contributes to 
reduce all-cause mortality, was highly significant whereas no significant changes were 
noticed neither for myocardial infarction nor for stroke [21]. Because of the reduction in CV 
mortality occurred already within the first few months, concomitant with a significant 
reduction in hospitalization for heart failure [30], an haemodynamic rather than an anti-
atherogenic effect has been suspected [31, 32]. This may be attributed to the diuretic 
(natriuretic/osmotic) activity of the SGLT2 inhibitor, which accompanied the glucuretic effect 
[33-37], although the so-called “diuretic hypothesis” has also been challenged [38, 39].   
In order to analyze the potential contribution of the reduction in BP in the diminution 
of CV events, CV mortality and all-cause mortality reported in EMPA-REG OUTCOME 
[21], the literature has been scrutinized looking for randomised controlled trials (RCTs) and 
meta-analyses having investigated 1) the effects of SGLT2 inhibitors on BP and CV 
outcomes; 2) the effects of lowering BP with different antihypertensive agents, including 
diuretics, on CV complications and mortality in patients with T2D. To identify relevant 




August 2016, with the following MESH terms :  T2D, BP, hypertension, diuretic, SGLT2 
inhibitor, on the one hand, and CV disease, coronary heart disease, myocardial infarction, 
stroke, heart failure and mortality, on the other hand. No language restrictions were imposed. 
Reference lists of original studies, narrative reviews and previous systematic reviews and 
meta-analyses were also carefully examined.  
1) Blood pressure lowering effects of SGLT2 inhibitors 
Treatment with SGLT2 inhibitors is consistently associated with a lowering of arterial 
BP in T2D patients with or without hypertension [26-29]. This effect has been confirmed with 
all SGLT2 inhibitors [29, 40]  : canagliflozin [41, 42], dapagliflozin [43-45], empagliflozin 
[46], ertugliflozin [47] (Table 1). Generally, the reduction in systolic BP was greater (at least 
twofold) than the reduction in diastolic BP. The BP reduction has been demonstrated when 
BP was controlled in seated position in the investigator office [28, 29, 45] or during 24h-
ambulatory monitoring [44-47] (Table 2). It has been suggested that circadian BP rhythm may 
represent a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes 
[48]. Circadian BP rhythm was maintained in these dedicated studies of SGLT2 inhibitors, 
with greater reductions in day-time versus night-time measurements observed for systolic BP 
[41, 44, 46] and diastolic BP [41, 46]. Thus circadian BP rhythm may represent a possible key 
target of SGLT2 inhibitors [48]. 
Overall, the average reduction may appear rather modest (Table 2). However, it is 
noteworthy that most trials with SGLT2 inhibitors were performed in T2D patients with rather 
well controlled BP at baseline. Post-hoc subgroup analyses have shown that greater BP 
reduction may be achieved in patients with higher BP levels at baseline (>140/90 mm Hg) 
[26, 27, 29, 49]. Canagliflozin, but not dapagliflozin and empagliflozin, showed a significant 
dose-response relationship with systolic BP reduction [29]. Interestingly, the reduction in BP 
induced by SGLT2 inhibitors is not accompanied by a significant increase in heart rate [49], 
arguing for an absence of sympathetic activation [50]. 
The BP lowering effect was also observed in patients already treated with a 
combination antihypertensive therapy [44], including renin-angiotensin blockers [51] or 
diuretics. However, the antihypertensive effect seems to be less marked when a SGLT2 
inhibitor was added to a diuretic. For instance, the reduction in seated systolic BP was almost 




beta-blocker or a calcium-channel blocker. Nevertheless, such a difference almost vanished 
when 24h- ambulatory SBP measurements were compared [44]. 
Because of their specific mechanism of action, SGLT2 inhibitors exert a lower 
glucose-lowering effect in patients in chronic kidney disease [52]. However, it has been 
demonstrated that in patients with moderate renal impairment, dapagliflozin still reduced 






2) Meta-analyses of RCTs having evaluated the effects of lowering BP 
in patients with T2D 
 
Several recent meta-analyses investigated the effects of lowering BP with different 
antihypertensive agents on CV outcomes in patients with T2D (Table 2) [9, 54-56]. In all 
these studies, results are expressed as standardised effects of a 10 mm Hg reduction in systolic 
BP.  All meta-analyses showed significant reductions in CV composite endpoints (MACEs), 
myocardial infarction, stroke and congestive heart failure (Table 2). All meta-analyses also 
reported a significant reduction in all-cause mortality. However, and surprisingly, only one 
meta-analysis reported data on CV mortality and it failed to demonstrate a significant 
reduction although a trend for better prognosis was observed (odds ratio or OR = 0.92;  
confidence interval or CI 95% 0.82-1.03) [56]. 
Most trials with antihypertensive agents have been performed in T2D patients with 
high BP at baseline, especially the UKPDS [4]. In contrast, baseline BP of T2D patients in 
EMPA-REG OUTCOME was rather well controlled, below 140/90 mm Hg on average [21]. 
Therefore, it is interesting to analyze the influence of baseline BP on the effects of lowering 
BP on CV outcomes in T2D patients with hypertension (Table 2).  In two meta-analyses 
which separated the whole population into two subgroups (high versus low baseline systolic 
BP), the reductions in major CV events, myocardial infarction, stroke, CV mortality and all-
cause mortality were significantly greater in patients with the higher systolic BP whereas such 




lower systolic BP at baseline (Table 2) [54, 56]. These observations were confirmed in 
another meta-analysis focusing on stroke (Table 2) [55].  The only disturbing results were 
reported in a meta-analysis which divided the whole population into 5 categories according to 
baseline systolic BP, from < 130 mm Hg to ≥160 mm Hg (Table 2) [9]. In this latter more 
sophisticated analysis, the influence of systolic BP at baseline did not appear clearly and CV 
protection was also present in T2D patients with systolic BP < 130 or 140 mm Hg at baseline 
(Table 2). 
3) Trials with different BP targets in patients with T2D 
BP targets in patients with T2D are controverted because results from RCTs were 
heterogeneous [12]. In the Hypertension Optimal Treatment (HOT)  trial,  18 790 patients 
were randomly assigned a target diastolic BP ≤ 80,  ≤ 85 or ≤  90 mm Hg [57]. The lowest 
incidence of major CV events occurred at a mean achieved diastolic BP of 82.6 mm Hg and 
the lowest risk of CV mortality occurred at 86.5 mm Hg. In the subgroup of 1501 patients 
with T2D at baseline, a decline in the rate of major CV events was seen in relation to the 
target group (P for trend=0·005). In the group randomised to diastolic BP ≤ 80 mm Hg the 
risk of major CV events was almost halved in comparison with that of the target group ≤ 90 
mm Hg. Interestingly, the difference was greater in diabetic than in nondiabetic patients [57]. 
The approximate halving of the risk was also observed for myocardial infarction, although it 
was not significant. Stroke also showed a declining rate with lower target BP groups, with a 
risk reduction of about 30% in the ≤ 80 mm Hg target group versus ≤ 90 mm Hg target group. 
CV mortality was also significantly lower in the ≤ 80 mm Hg target group than in each of the 
other target groups ≤ 85 or ≤ 90 mm Hg, but these results should be taken with caution 
because of a rather low number of events (Table 3) [57]. 
In a large RCT in T2D patients at high CV risk ((Action to Control Cardiovascular 
Risk in Diabetes, ACCORD-BP) [58], targeting a systolic BP of less than 120 mm Hg, as 
compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal 
and nonfatal major CV events. No reduction was observed regarding myocardial infarction, 
heart failure, CV mortality and all-cause mortality. The only significant reduction concerned 
stroke (-41%, P = 0.01) (Table 3).   
To evaluate the effects of achieved systolic BP during antihypertensive treatment on 
CV outcomes, event rates of a composite primary endpoint (CV death or nonfatal myocardial 




of <140 mm Hg, <130 mm Hg, and <120 mm Hg were measured in 6459 patients with 
diabetes and 4246 patients without diabetes from the ACCOMPLISH (Avoiding 
Cardiovascular Events in Combination Therapy in Patients Living With Systolic 
Hypertension) substudy [59] . In the diabetic cohort (6459 patients), the primary endpoint was 
49% lower (P < 0.001) at <140 mm Hg than at ≥ 140 mm Hg, and the separate components of 
this endpoint were also significantly reduced (Table 3). Further systolic BP reductions did not 
improve outcomes, and at <120 mm Hg they were no longer different (except for stroke : -
56%, P = 0.0120) from ≥ 140 mm Hg [59].  
In contrast, in the nondiabetic cohort, the primary endpoint event rate fell steadily 
(although not significantly) through the decreasing systolic BP categories until it was reduced 
by 45% (P = 0.0413) at <120 mm Hg. Total stroke rate was lowest at <120 mm Hg (-68%, P 
= 0.0067) [59]. These results in patients at high risk for CV events but without diabetes were 
confirmed in the recent SPRINT trial [60]. In the latter study, targeting a systolic BP of less 
than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and 
nonfatal major CV events, heart failure, CV mortality and death from any cause [60] (Table 
3). 
According to a meta-analysis of RCTs published in 2005, there was limited evidence 
that lower BP goals produce larger reductions in total MACEs in individuals with versus 
without diabetes, and the short- to medium-term effects on MACEs of various BP-lowering 
regimens studied in the literature were broadly comparable for patients with and without 
diabetes [61]. At the present time, evidence from RCTs does not support BP targets lower 
than the standard targets in people with elevated BP and T2D [12].  On the contrary, taken 
altogether, available results rather suggest that T2D patients (<140 mm Hg or <130 mm Hg) 
and nondiabetic patients (<120 mm Hg) may require different systolic BP targets for optimal 
CV protection, although stroke and renal considerations should also influence the selection of 
BP targets [62].  
 
4) Cardiovascular outcome results in EMPA-REG OUTCOME vs 
other major RCTs with antihypertensive agents in patients with 
T2D 
The first landmark study in patients with T2D was the UKPDS study [4]. This trial 
recruited patients with newly diagnosed T2D. BP was rather high at baseline and patients 




average reduction in systolic BP reached 10 mm Hg. This was associated with a significant 
reduction in CV events, stroke and CV mortality. The reduction in myocardial infarction and 
all-cause mortality did not reach statistical significance (Table 4). These results are in 
agreement with those reported in meta-analyses having studied the effects of a 10 mm Hg 
systolic BP reduction in patients with T2D (see comment above and table 2). However, it is 
quite hazardous to compare the results of EMPA-REG OUTCOME with those of UKPDS. 
Indeed, in the UKPDS, in contrast to EMPA-REG OUTCOME, patients were not selected 
upon CV antecedents and did not receive standard therapy to reduce CV risk throughout the 
study, the initial BP was higher, the treatment-associated BP drop was greater, and the 
duration of the follow-up was much longer. 
In this regard, MICRO-HOPE [6] and ADVANCE-BP [7] are other major placebo-
controlled trials with characteristics closer to those of EMPA-REG OUTCOME because they 
recruited T2D patients who were aged 55 years or older, and who had a history of CV disease 
or at least another CV risk factor.  Both studies tested the effects of blocking the renin-
angiotensin system with an ACE inhibitor, either alone (enalapril in MICRO-HOPE) [6] or in 
combination with a diuretic (fixed combination of perindopril and indapamide in ADVANCE-
BP) [7]. In both trials, baseline BP levels were only slightly above those in EMPA-REG-
OUTCOME and the average BP reduction with the antihypertensive therapy was in the same 
order of magnitude (Table 4). After a mean follow-up of around 4-5 years, reductions in 
composite CV events, myocardial infarction, stroke, heart failure, CV mortality and all-cause 
mortality were observed in both MICRO-HOPE and ADVANCE-BP. The CV protection 
observed in EMPA-REG OUTCOME trial appears almost similar to that reported in these two 
trials (Table 4). One major difference, however, is that a large majority (81%) of patients in 
EMPA-REG OUTCOME were already treated with a blocker of the renin-angiotensin system 
combined with other CV protective agents (statins, antiplatelet compounds, …) [21]. Thus 
empagliflozin provided an additional protection in T2D patients with antecedents of CV 
disease but already receiving optimal standard therapy. The presence of T2D and previous CV 
disease markedly increases the risk of recurrent CV events and thus should increase the 
absolute benefit resulting from a lowering of BP [2]. This high CV risk at baseline might be 
of importance. Indeed, a recent trial showed that therapy with candesartan plus 
hydrochlorothiazide was not associated with a lower rate of major CV events than placebo 
among persons at intermediate risk (at least one CV risk factor among which dysglycaemia 






5) Meta-analyses of trials with cardiovascular outcome results : 
comparison between diuretic agents and SGLT2 inhibitors 
The mode of action of empagliflozin targeting the kidney may mimic that of a diuretic 
and a “diuretic hypothesis” has been put forward to explain the early and marked CV 
protection in EMPA-REG OUTCOME [33-37]. Therefore, the comparison of the CV effects 
of empagliflozin in EMPA-REG OUTCOME with those of different diuretics deserves further 
attention. A recent network meta-analysis of studies with both placebo-treated or untreated 
controls and with actively treated controls analyzed health outcomes associated with various 
antihypertensive therapies used as first-line agents in the general population. It concluded that 
low-dose diuretics are the most effective first-line treatment for preventing the occurrence of 
cardiovascular disease morbidity and mortality [64].  Furthermore, reduction in arterial BP is 
very effective in preventing heart failure and diuretics may be superior to other 
antihypertensive therapies in this respect [65]. Thiazide diuretics, including thiazide-type 
(chlorothiazide and hydrochlorothiazide) and thiazide-like diuretics (indapamide and 
chlorthalidone), have been used for the treatment of hypertension for more than 5 decades and 
are still the most popular diuretics. Even it has been suggested to use more diuretics to attain 
target BP in diabetic hypertensive patients [66, 67], available results in patients with T2D are 
scarce and largely incomplete. As an example, three meta-analyses investigating the effects of 
thiazides and thiazide-like diuretics on CV outcomes did not mention the diabetic population 
(Table 5) [64, 68, 69]. Overall, the reduction in CV events mainly concerned stroke and heart 
failure whereas the effects on myocardial infarction and coronary events was less pronounced 
and generally not statistically significant. The reduction in mortality averaged 10 to 20 % and 
was borderline significant. In contrast to has been reported in one meta-analysis [55], another 
meta-analysis [68] suggested that thiazide-like diuretics have greater protective effect against 
CV events than thiazide-type diuretics, especially on heart failure. 
 Table 5 summarizes results published in a few meta-analyses focusing on the effects 
of different diuretics, mainly thiazides in patients with T2D patients with hypertension [70, 
71] and mineralocorticoid receptor antagonists in T2D patients with heart failure [72-74] (no 
such available data for loop diuretics in T2D patients). These results were compared with 
results reported in two meta-analyses assembling data obtained with SGLT2 inhibitors in T2D 
patients (all patients not selected for the presence of hypertension or heart failure) [75, 76]  




compared to classic diuretics, whatever the outcome considered (Table 5). Strokes represent 
the only exception, because they were significantly reduced whereas a trend to a modest 
increase was reported with SGLT2 inhibitors, a finding mainly driven by the results of 
EMPA-REG OUTCOME [21]. 
As previously discussed, available data do not support a major contribution of the 
diuretic effect of empagliflozin in the reduction in CV and all-cause mortality in EMPA-REG 
OUTCOME, even if conclusions drawn from indirect comparison require caution [38, 39]. 
 
6) Post-hoc analyses of EMPA-REG OUTCOME 
The protective effect of empagliflozin was observed independently of the baseline 
level of BP :  CV mortality : HR = 0.56 (0.40, 0.79) in patients with systolic BP ≥140 mmHg 
and/or diastolic BP ≥90 mmHg vs HR = 0.67 (0.50, 0.91) in patients with systolic BP < 140 
mmHg and/or diastolic BP <90 mmHg [21]. Whereas the use of lipid-lowering agents and 
antiplatelet/anticoagulant agents was similar in patients receiving empagliflozin or placebo 
throughout the study, the use of antihypertensive agents was less pronounced in patients 
treated with empagliflozin than in those receiving placebo [21]. This imbalance may 
contribute to dampen the difference in BP between the two groups. Subgroups analyses 
comparing CV outcomes in T2D patients with marked versus modest reduction in BP with 
empagliflozin therapy would be of great interest to further appreciate the role of BP lowering 
in the overall CV protection but this information is not available yet.  
Subgroup analyses suggest that the background antihypertensive therapy does not 
significantly alter the effect of empagliflozin. The vast majority of participants in the EMPA-
REG OUTCOME study were treated with drugs inhibiting the renin-angiotensin system. It 
has been postulated that in patients treated with angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers, empagliflozin could have had additive cardioprotective effects 
through the activation of non-classic renin-angiotensin system pathways, i.e. activation of the 
AT2 receptor and the Angiotensin 1–7 pathway, with an anti-proliferative, anti-inflammatory, 
anti-arrhythmic, vasodilatory effect [77]. 
Almost one third of patients participating to EMPA-REG OUTCOME had impaired 
renal function with an estimated glomerular filtration rate < 60 ml/min/m² (eGFR = 48.4 
ml/min/m²) and a prespecified analysis compared them with patients with normal kidney 




baseline BP control as patients with normal kidney function (136.1/74.5 mm Hg versus 
135.0/77.4 mm Hg, respectively), but received more antihypertensive agents, especially 
diuretics (58.6 % vs 38.5% of patients, respectively). Incident or worsening nephropathy or 
cardiovascular death was significantly reduced with empagliflozin compared with placebo in 
patients with prevalent kidney disease defined as eGFR <60 mL/min/1.73m² and/or 
macroalbuminuria at baseline (HR = 0.64; 95% CI 0.53, 0.76; P <0.001) [21, 78]. Thus 
cardiorenal protection appears to be of the same magnitude in patients at high risk of CV 
disease with chronic kidney disease at baseline as in those without renal impairment. 
Finally, there was no reduction in stroke in EMPA-REG OUTCOME (a non-
significant increase was even reported, partially driven by the occurrence of cerebrovascular 
events within the month following treatment interruption) whereas antihypertensive agents, 
and especially diuretics, are known to be particularly effective in preventing stroke in 
hypertensive patients [66].  Thus, the absence of reduction in stroke (and possibly an 
increased risk) in EMPA-REG OUTCOME is surprising. However, these results may be 
explained by the rather good BP control at baseline in the population of EMPA-REG-
OUTCOME [21]. Indeed, at least two meta-analyses having investigated the influence of 
baseline BP on CV outcomes suggest that the reduction in the incidence of stroke by 
antihypertensive therapies were no longer significant in T2D patients with baseline systolic 
BP < 140 mm Hg (see table 2) [55, 56], which was the case in EMPA-REG OUTCOME [21]. 
 
Conclusion 
EMPA-REG OUTCOME reported a marked reduction in CV mortality and all-cause 
death rate with the SGLT2 inhibitor empagliflozin, together with a significant reduction in 
hospitalization for heart failure, in T2D patients with antecedents of CV disease. Obviously, 
these results cannot be explained by the modest improvement in glucose control. SGLT2 
inhibitors induce a consistent BP reduction although the contribution of this effect to the 
better CV outcomes is unclear. A CV protection has also been reported with various 
antihypertensive agents but generally in patients with higher BP at baseline and showing a 
greater reduction in BP as compared to patients of EMPA-REG OUTCOME. Although a 
diuretic hypothesis has been proposed to explain most of the benefit, comparison with 
available data published with classic diuretics, especially thiazides, does not allow to fully 
support this hypothesis. Thus, although BP reduction associated to empagliflozin therapy may 




probably play a greater role in the overall CV protection and reduction in mortality observed 
in this trial.  
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All trials in T2D patients with or without hypertension (investigator office blood pressure measurement) Placebo-subtracted changes 
All SGLT2 Baker et al 
2014 [29] 
12960 -3.96 -4.41 -3.51 -1.59 -2.18 -1.01 
Placebo controlled 
RCTs 
7875 -3.82 -4.40 -3.23 -1.45 -1.81 -1.08 
Active controlled RCTs 5085 -4.17 -4.88 -3.46 -1.87 -2.33 -1.40 
Canagliflozin 5607 -4.38 -5.08 -3.69 -2.02 -2.48 -1.56 
Dapagliflozin 5280 -3.78 -4.49 -3.07 -1.41 -1.86 -0.96 
Empagliflozin 1359 -3.02 -4.25 -1.80 -1.01 -1.72 -0.31 




al 2016 [40] 
       
Canagliflozin 100 mg 7853 -3.89 -4.90   -2.88 -1.64 -2.25 -1.03 
Canagliflozin 300 mg -4.87 -5.87    -3.87 -2.03 -2.63 -1.44 
Dapagliflozin 5 mg 7681 -2.84 -4.14    -1.54 -1.53 -2.48 -0.59 
Dapagliflozin 10 mg -3.01 -3.89 -2.13 -1.74 -2.58 -0.89 
Empagliflozin 10 mg 8463 -3.33 -4.25 -2.41 -1.65 -2.20 -1.10 
Empagliflozin 25 mg -3.66 -4.54 -2.77 -1.91 -2.44 -1.38 
Trials in T2D patients with hypertension (24h-ambulatory blood pressure monitoring) Placebo-subtracted changes 
Canagliflozin 100 mg 
Townsend  
et al 2016 
[41] 
57 vs 56 
24-h 
-3.3  -6.7 +0.2 -1.9 -4.0 +0.1 
Daytime -4.0 -7.5 -0.5 -2.2 -4.3 -0.1 
Nighttime -0.9 -5.1 3.3 -2.4 -4.9 0.2 
300 mg 
Townsend  
et al 2016 
56 vs 56 
24-h 
 







Daytime -5.4 -8.9 -1.9 -3.0 -5.0 -0.9 
Nighttime -3.0 -7.2 1.1 -0.8 -3.4 1.8 
Dapagliflozin 10 mg 
Lambers 
Heerspink 




25 vs 24  
24-h 
-5.6 -10.3 -1.0 NA NA NA 
Daytime -8.8 -13.7 -3.9 NA NA NA 
Nighttime -6.0 -11.1 -1.0 NA NA NA 
10 mg 
Weber et al 
2016 [44] 
187 vs 186 
24-h 
-4.45   -7.14 -1.76 NA NA NA 
Daytime -4.76 -7.52 -2.0 -1.86 -3.64 -0.08 
Nighttime -3.88 -6.85 -0.90 -2.11 -4.00 -0.23 
Empagliflozin 10 mg 
Tikkanen et 
al 2015 [46] 
 
276 vs 271 
24-h 
-3.44 -4.78 -2.09 -1.36 -2.15 -0.56 
Daytime -3.94 -5.37 -2.52 -1.56 -2.42 -0.69 
Nighttime -2.50 -4.09 -0.91 -0.95 -1.93 0.03 
25 mg 
Tikkanen et 
al 2015 [46] 
 
276 vs 271 -4.16 -5.50 -2.83 -1.72 -2.51 -0.93 
Daytime -4.78 -6.20 -3.36 -1.98 -2.84 -1.12 
Nighttime -2.90 -4.48 -1.32 -1.15 -2.12 -0.18 
Ertugliflozin 5 mg  
Amin et al 
2015 [47] 
(**) 
38 vs 38 
24-h 
-3.93 -6.10 -1.76 
 
-3.09 -4.53 -1.65 
Daytime -4.34 -6.67  -2.01 -2.69 -4.19 -1.18 
Nighttime -3.18 -6.06 -0.30 -3.55 -5.58 -1.51 
25 mg 
Amin et al 
2015 [47] 
(**) 
39 vs 38 -3.62 -5.71 -1.54 
 
-2.24 -3.63 -0.86 
Daytime -4.89 -7.14 -2.65 -2.58 -4.03 -1.13 





BP : blood pressure. NA not available  
(*) Results expressed as absolute changes rather than placebo-subtracted changes 




Table 2 : Recent meta-analyses of randomised controlled trials having investigated the effects of  lowering blood pressure (all antihypertensive 
agents combined) on cardiovascular outcomes in patients with hypertension and type 2 diabetes and the influence of baseline blood pressure. 
Results are expressed as standardised effects of a 10 mm Hg reduction in systolic blood pressure (mean hazard ratio with 95% confidence 
interval and P value). 












































































































Brunström et al 2016 
[56] 
 
Pooled data (any BP 
level) 
 






0.92 (0.87 to 
0.96) 
0.82 (0.75 to 
0.89) 
















1.01) 1.05) 0.98) 0.97) 
 










Xie et al 2016 [55] Pooled data (any BP 
level) 
NA NA 0.74 (0.66-
0.83) 
NA NA NA 
≥ 140 NA NA 0.71 (0.63-
0.80) 
NA NA NA 
< 140 NA NA 0.90 (0.69-
1.17) 
NA NA NA 




































Targeting diastolic BP 





BP ≤ 90 




























BP ≤ 90 





























140 mm Hg 
2362 vs 
2371 































































































≥ 140 mm 
Hg 
150.4/78.1 1.16) 0.85) 1.39) 
SPRINT [60] 
Patients at high 





140 mm Hg 
4678 vs 
4683 

























Table 4 : Comparison of cardiovascular outcome results in EMPA-REG OUTCOME and other major trials having evaluated an antihypertensive 
therapy in patients with T2D.  






















































Enalapril 1808 vs 
1769 
4.5 142/80 2.5/1 0.75 (0.64-
0.88) 
















































Empagliflozin 4687 vs 
2333 
3.1 135.3/76.6 ~ 4/1 0.86 (0.74-
0.99) 

























 (*) Mortality related to diabetes rather than CV mortality 
(**) Hospitalisation for heart failure 
(***) HR = 0.56 (0.40, 0.79) in patients with baseline SBP ≥ 140 and/or DBP ≥ 90  mm Hg  vs HR = 0.67 (0.50, 0.91) in patients with baseline 




Table 5 : Comparison of cardiovascular outcome results in meta-analyses of trials with diuretics and with SGLT2 inhibitors.   







Stroke CV mortality All-cause 
mortality 
Heart failure 
Meta-analyses in a general population 
Psaty et al 









P = NA 
0.79 
(0.69-0.92) 
P = NA 
0.71 
(0.63-0.81) 
P = NA 
0.81 
(0.73-0.92) 
P = NA 
0.90  
(0.84-0.96) 
P = NA 
0.51 
(0.42-0.62 







P = 0.007) 
0.95 
(0.85-1.06) 
P = 0.378) 
0.92 
(0.75-1.13) 
P = 0.438 
NA NA 0.62 
(0.49-0.79) 







P = 0.278) 
0.96 
(0.78-1.19) 
P = 0.725) 
1.03 
(0.67-1.56) 
P = 0.907 
NA NA 0.71 
(0.44-1.15)  







P < 0.001), 
0.98 
(0.91-1.05) 
P = 0.565 
0.82 
(0.70-0.96) 
P = 0.016). 
NA NA 0.57 
(0.43-0.76) 
P < 0.001)  
Olde 
Engberink 
et al 2015 
[69] 




























Meta-analyses in a population with T2D 
Lièvre et al 
2000 [70] 








P = 0.23 
0.637 
(0.45-0.90) 
P = 0.011 
0.85 
(0.64-1.13) 
P = 0.27 
0.952  
(0.82-1.23) 
P = 0.65 
NA 
Remonti et 
al 2016 [71] 


























placebo P = 0.04 P< 0.0001 
Wu et al 
2016 [75] 
All types All SGLT2i 
versus all 
comparators 
NA (b) 0.84 
(0.75-0.95) 
P = 0.006 
0.88 
(0.72-1.07)  






P < 0.0001 
0.71  
(0.61-0.83) 




al 2016 [76] 
All types All SGLT2i 
versus all 
comparators 
NA (b) NA 0.77 
(0.63-0.94) 
P < 0.01 
1.09 
(0.86-1.38) 
P = 0.50 
0.43 
(0.36-0.53) 
P < 0.001 
0.70  
(0.59-0.83) 
P < 0.001 
NA 
 
CV : cardiovascular. NA : not available. HCT : hydrochlorothiazide. SGLT2i : SGLT2 inhibitors.T2D : type 2 diabetes 
(a): Not available but data reported in other meta-analyses : Spironolactone : reduction in systolic/diastolic BP : -9.4/-3.8 mm Hg [72] in patients 
with arterial hypertension. Eplerenone : reduction in systolic/diastolic BP: -8.07/-4.08 in patients with mild to moderate hypertension [74].  
(b) Not available but data reported in other meta-analyses Hg (see meta-analysis by Baker et al in Table 1 [29]): reduction in systolic/diastolic BP 
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-        Empagliflozin reduces mortality in diabetic patients with cardiovascular disease. 
-        A reduction in blood pressure could contribute to better outcomes with empagliflozin. 
-        Empagliflozin improves prognosis more than did antihypertensive agents (diuretics). 
-        Other mechanisms should explain the cardiovascular protection in EMPA-REG 
OUTCOME. 
 
 
